Johnson & Johnson (JNJ) FY2025 Earnings Quality Report

Grade: F — Cash Coverage and Goodwill Expansion

Framework: Schilit *Financial Shenanigans* + Beneish M-Score + forensic accounting principles

Data: SEC EDGAR 10-K (Filed 2026-02-11) + Yahoo Finance

Auditor: PricewaterhouseCoopers LLP — Clean opinion (2 critical audit matters: U.S. Innovative Medicine rebate reserves; talc litigation contingencies)

One-line verdict: J&J's F grade comes from two fails — $20.1B of cash covers only 42% of $47.9B of debt, and $99.2B of goodwill plus intangibles equals 122% of the $81.5B equity base. Two watches add color: AR growth of 15.7% outpaces revenue growth of 6.0%, and other non-current assets grew 25.9%. The underlying business is exceptionally strong: 6.0% revenue growth to $94.2B, net income of $26.8B, operating cash flow of $24.5B, Debt/EBITDA of 1.2x, and M-Score at -2.26 (just barely in the safe zone). The balance sheet leverage is the direct consequence of a $17.5B acquisition spend in FY2025 — primarily the $14.6B Intra-Cellular Therapies deal that brought CAPLYTA into the Innovative Medicine portfolio. This is an M&A-driven leverage story on top of an otherwise pristine healthcare conglomerate.

Two Global Segments: Innovative Medicine and MedTech

J&J operates in two reportable segments after the 2023 Kenvue consumer health spinoff:

Innovative Medicine — $60.4B in FY2025 sales, up 6.0% from FY2024. From the MD&A: "Innovative Medicine segment sales in 2025 were $60.4 billion, an increase of 6.0% from 2024, which included operational growth of 5.3% and a positive currency impact of 0.7%. U.S. sales were $36.3 billion, an increase of 7.0%."

MedTech — $33.8B in FY2025 sales, up 6.1% from FY2024. From the MD&A: "MedTech segment sales in 2025 were $33.8 billion, an increase of 6.1% from 2024, which included operational growth of 5.4% and a positive currency impact of 0.7%. U.S. sales were $17.4 billion."

Total worldwide sales of $94.2B reflect a balanced geographic mix: $53.8B U.S. (57%) and $40.4B international (43%).

The STELARA Decline and the Oncology Engine

The FY2025 results include a major negative: the loss of exclusivity on STELARA to biosimilar competition. From the MD&A: "In the fiscal year 2025, the negative impact of the STELARA sales decline, due to biosimilar competition, was approximately 6.2%, 7.6% and 4.4% on worldwide, U.S. and international operational sales, respectively."

That STELARA lost $4.3B in sales in one year (from $10.4B to $6.1B). TREMFYA's $1.5B growth partially offset the decline, but immunology total sales fell 11.8%.

Oncology was the standout growth engine:

From the MD&A: "Oncology products achieved sales of $25.4 billion in 2025, representing an increase of 22.1% as compared to the prior year. Strong sales of DARZALEX (daratumumab) were driven by continued share gains and market growth... Increased sales of CARVYKTI (ciltacabtagene autoleucel) were driven by continued share gains and capacity expansion. Additionally, sales from the ongoing launches and share gains of TECVAYLI (teclistamab-cqyv), TALVEY (talquetamab-tgvs) and RYBREVANT (amivantamab)/LAZCLUZE (lazertinib) contributed to the growth."

Net income moves dramatically year to year due to spinoff gains, large litigation charges, and acquisition-related items. The FY2023 spike reflects the Kenvue spinoff; the FY2024 dip reflects talc settlement reserves; FY2025 normalizes.

The Intra-Cellular Therapies Acquisition and the Goodwill Surge

The defining balance sheet event of FY2025 was the acquisition of Intra-Cellular Therapies, which closed April 2, 2025. From the cash flow summary: "Cash flow used for investing activities of $23.6 billion was primarily due to: (Dollars in billions) $(4.8) additions to property, plant and equipment (17.5) acquisitions, net of cash acquired."

The acquisition brought CAPLYTA into the portfolio, which the MD&A breaks out as a standalone neuroscience product: "CAPLYTA (3) 700 * *" — $700M of contribution in the partial year. The Intra-Cellular deal was $14.6B in consideration per the closing disclosures.

The Intra-Cellular deal directly added ~$12.8B of intangibles (CAPLYTA product rights) and required J&J to issue ~$11.3B of additional debt. Goodwill grew 10%, intangibles grew 34%. From the MD&A: "Total Change Operations Change Currency Change Total Oncology $25,380 $20,781 22.1 % 20.9 % 1.2 %"

Cash Flow: $24.5B of Operations, Well Supported

From the 10-K: "Cash flow from operations of $24.5 billion was the result of: $26.8 Net Earnings; 10.4 non-cash expenses and other adjustments primarily for depreciation and amortization, stock-based compensation, asset write-downs, charges for acquired in-process research and development and deferred tax provision partially offset by net gain on sale of assets/businesses; (6.2) an increase in other current and non-current assets; (5.7) a decrease in other current and non-current liabilities; 2.4 an increase in accounts payable and accrued liabilities; (3.2) an increase in accounts receivable and inventories."

The $3.2B growth in AR and inventories is the direct source of the A2 watch flag. CFFO/NI of 0.92 is tight for J&J historically — the company normally runs above 1.0 — reflecting the working capital consumption in FY2025.

The 18-Point Screening

Revenue Quality

A2 watch: AR grew from $14.84B to $17.18B (+15.7%) while revenue grew 6.0%. The gap is partly from Intra-Cellular integration (AR balances added to consolidated books), partly from working capital expansion. DSO expanded by 6 days from 61 to 67 — within normal pharmaceutical wholesaler cycles but trending the wrong direction.

Expense Quality

Cash Flow Quality

C4 fail: $20.1B of cash plus short-term investments against $47.9B of total debt produces 42% coverage. At $19.3B of annual FCF, the company can service and pay down the debt without strain, but the mechanical ratio fails the screen.

Balance Sheet

D1 fail: Goodwill of $48.77B plus other intangibles of $50.40B = $99.17B, or 122% of the $81.54B equity base. The absolute number grew by $17.4B in FY2025 alone. Debt/EBITDA of 1.2x is very healthy — the leverage problem is goodwill relative to equity, not debt relative to earnings.

D3 watch: Other non-current assets grew 25.9% as Intra-Cellular integration added new balance sheet items.

M&A Risk

E2 close to threshold: goodwill plus intangibles grew 21% YoY, below the 30% surge threshold but elevated. Continued large M&A would move this into watch territory.

Beneish M-Score

M-Score at -2.26 sits right at the -2.22 threshold — the thinnest pass in the 10-company set. The DSRI component (driven by the AR surge) is pulling the score toward the edge.

Key Risks from Item 1A

1. Competition and patent exclusivity loss. From the 10-K: "The Company's businesses operate in highly competitive product markets and competitive pressures could adversely affect the Company's earnings... For the Company's Innovative Medicine businesses, loss of patent exclusivity for a product often is followed by a substantial reduction in sales as competitors gain regulatory approval for generic, biosimilar and other competing products and enter the market." STELARA's 41% decline in FY2025 is the current proof of this risk.

2. Manufacturing interruption and supply chain. "Interruptions and delays in manufacturing operations could adversely affect the Company's business, sales and reputation. The Company's manufacturing of products requires the timely delivery of sufficient amounts of complex, high-quality components and materials."

3. Acquisition integration and execution risk. From the 10-K: "The Company may also experience operational and financial risk in connection with acquisitions if we are unable to fully identify potential risks and liabilities associated with acquired businesses or products, successfully integrate operations and employees, and successfully identify and realize synergies with existing businesses while containing acquisition-related strain on our management, operations and financial resources."

4. U.S. Innovative Medicine rebate reserves (critical audit matter #1). From PwC: "A significant portion of the liability related to rebates is from the sale of pharmaceutical products within the U.S., primarily the Managed Care, Medicare and Medicaid programs, which amounted to $13.0 billion as of December 28, 2025." That $13.0 billion rebate reserve is one of the largest estimates on the balance sheet, and any change flows directly through revenue.

5. Talc litigation contingencies (critical audit matter #2). From PwC: "a significant number of personal injury claims alleging that talc causes cancer have been asserted against the Company and its affiliates arising out of the use of body powders containing talc, primarily JOHNSON'S Baby Powder. The Company records accruals for loss contingencies associated with legal matters, including talc, when it is probable that a liability will be incurred and the amount of the loss can be reasonably estimated." The 10-K notes: "For these matters, management is unable to estimate the possible loss or range of loss beyond the amounts accrued."

6. Medicare Part D redesign and pricing pressure. The MD&A explicitly calls out "the impact of Medicare Part D redesign" as a drag on multiple products including ERLEADA and IMBRUVICA. The redesign shifts costs to manufacturers — a structural headwind for the Innovative Medicine portfolio.

7. Wholesaler concentration. "In 2025, the Company utilized three wholesalers distributing products for both segments that represented approximately 21.8%, 15.5% and 11.1% of the total gross revenues." Roughly 48% of J&J's total revenue flows through just three distributors (McKesson, Cencora, and Cardinal Health).

Altman Z-Score and F-Score

Z-Score of 1.91 sits in the middle of the grey zone. The high goodwill-to-equity ratio and working capital timing pull the score down from what the operating cash flow profile alone would support.

Summary

Grade: F. Two fails (Cash vs Debt, Goodwill+Intangibles) driven by the $17.5B Intra-Cellular Therapies acquisition.

J&J's F grade tracks the direct financial consequences of one specific decision: the $14.6B acquisition of Intra-Cellular Therapies in April 2025. That single deal added approximately $12.8B of intangibles, pushed goodwill-plus-intangibles to $99.2B (122% of equity), and required $11.3B of incremental debt that cut the cash-to-debt coverage ratio to 42%.

The underlying business quality remains high: Oncology grew 22% driven by DARZALEX, CARVYKTI and the multiple myeloma franchise; MedTech grew 6.1% with Shockwave integration; FCF hit $19.3B; Debt/EBITDA is 1.2x (deeply healthy for an investment-grade pharma); and the M-Score at -2.26 just barely passes the manipulation threshold. The STELARA biosimilar erosion (-41.3%) is a meaningful headwind but TREMFYA's 40.5% growth is partially filling the gap.

The real risks, per the 10-K's own risk factors and PwC's critical audit matters, are: (1) the $13.0B U.S. rebate reserve estimation; (2) talc litigation contingencies that PwC specifically flags as unestimable beyond existing accruals; (3) further biosimilar erosion across the immunology portfolio; and (4) Medicare Part D redesign compressing pharma pricing. Earnings-quality risk is contained — the F grade captures the balance sheet adjustment from M&A, not operational deterioration.

**Disclaimer**: This report is based on Johnson & Johnson's FY2025 10-K (SEC EDGAR) and public financial data. This is NOT investment advice.

Data: SEC EDGAR 10-K (Filed 2026-02-11) + Yahoo Finance

Auditor: PricewaterhouseCoopers LLP (Unqualified opinion, 2 critical audit matters)